Successful Treatment of Chronic Myelogenic Leukemia (CML) with Imatinib after Renal Transplantation

Ali Eishei Oskuei, Khadijeh Makhdoomi^*, Sara Vossoghian, Mohsen Farrokhpour

*Corresponding Author: Email: Makhdoomikhadijeh@yahoo.com

Abstract

Chronic Myelogenic Leukemia (CML) is a rare malignant disorder after solid organ transplantation, especially in renal transplant recipients. Imatinib Mesylate is currently approved as first line treatment of CML. Most reports on CML are from kidney recipients who received azathioprine in combination with cyclosporine and prednisolone as immunosuppressive therapy. We report a case with CML who was treated with Mycophenolate Mofetil.

First Name

Last Name

Email Address

Comments

Security code

Generate New Image

Type the code from the image

Abstract View: 2448

years	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2024	29	23	24	20	17	12	22	25	35	42	52	7
2023	37	18	32	31	33	27	26	21	32	28	30	23
2022	38	30	30	38	33	34	34	33	34	35	36	30
2021	27	30	38	33	41	50	49	48	54	38	33	39
2020	38	40	46	47	39	29	38	30	37	32	26	28
2019	29	24	21	30	27	17	22	32	18	30	25	43
2018	10	7	8	10	5	11	10	14	11	10	17	31
2017											15	10

PDF Download: 1360

years	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2024	11	15	7	11	6	14	15	9	15	16	12	1
2023	18	12	22	21	21	25	28	25	26	19	23	21
2022	13	18	21	15	16	22	14	16	22	22	20	32
2021	16	11	12	16	13	19	14	19	20	17	23	31
2020	8	16	18	17	31	15	13	14	13	12	11	12
2019	23	15	10	10	17	11	7	6	6	7	10	24
2018	14	13	17	18	10	12	14	9	6	8	15	24
2017											17	22